Regulatory

Regulatory  ·  Weekly Digest 24 Feb 2024
Mabwell receives IND Approval from FDA for Novel B7-H3 ADC 7MW3711

Weekly Digest – Feb 2024 Weekly Digest – Feb 2024 21 Feb 2024: Mabwell receives IND Approval from FDA for Novel B7-H3 ADC 7MW3711 The IND application is for advanced malignant solid tumors, and the clinical trial for 7MW3711 has […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest 24 Feb 2024
Datopotamab deruxtecan’s BLA accepted in the US for advanced NSCLC in previously treated patients

Weekly Digest – Feb 2024 Weekly Digest – Feb 2024 19 Feb 2024: Datopotamab deruxtecan’s BLA accepted in the US for advanced NSCLC in previously treated patients Datopotamab Deruxtecan is a TROP2-directed DXd antibody-drug conjugate (ADC) being jointly developed by […]

by Sandhya Ramalingam

Continue Reading